文献速递食管胃疾病与幽门螺杆菌消化道出血

伏诺拉生预防低剂量阿司匹林相关溃疡复发:随机3期研究

Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
PubMed 文献 · Gut · 2017-12-01

在104个日本中心纳入621例需长期低剂量阿司匹林治疗且有消化性溃疡史的患者,随机接受兰索拉唑15mg、伏诺拉生10mg或20mg每日一次治疗24周并延伸治疗≤2年。24周溃疡复发率分别为2.8%、0.5%和1.5%,伏诺拉生非劣于兰索拉唑;延伸研究事后分析中伏诺拉生10mg复发率显著低于兰索拉唑15mg。

要点

  • 24周溃疡复发率:兰索拉唑15mg组2.8%,伏诺拉生10mg组0.5%,伏诺拉生20mg组1.5%。
  • 伏诺拉生10mg和20mg在24周研究中非劣于兰索拉唑15mg(界值8.7%)。
  • 延伸研究事后分析:伏诺拉生10mg复发率显著低于兰索拉唑15mg(P=0.039),20mg组未达显著(P=0.260)。

核心结论

  • 伏诺拉生10mg和20mg在低剂量阿司匹林治疗期间预防消化性溃疡复发与兰索拉唑15mg同样有效,长期安全性相似且耐受良好。

研究设计与样本

  • 双盲、随机、非劣效性研究,以及单盲延伸研究,在104个日本中心开展。
  • 纳入621例需长期低剂量阿司匹林治疗且有消化性溃疡史的患者,其中439例进入延伸研究。
  • 患者按1:1:1计算机随机接受兰索拉唑15mg(n=217)、伏诺拉生10mg(n=202)或伏诺拉生20mg(n=202)每日一次,双盲治疗24周,延伸治疗≤2年。

主要发现

  • 24周溃疡复发率:兰索拉唑15mg组2.8%,伏诺拉生10mg组0.5%,伏诺拉生20mg组1.5%。
  • 伏诺拉生非劣于兰索拉唑(Farrington and Manning检验:界值8.7%,显著性水平2.5%)。
  • 延伸研究事后分析中,与兰索拉唑15mg相比,伏诺拉生10mg的溃疡复发率显著更低(log-rank检验,P=0.039),伏诺拉生20mg未达显著(P=0.260)。
  • 在24周研究和延伸研究中,兰索拉唑组的消化道出血率均高于两个伏诺拉生剂量组。

关键数值与推荐

  • 主要结局为24周(双盲期)溃疡复发率,非劣效界值8.7%,显著性水平2.5%。
  • 24周溃疡复发率:兰索拉唑15mg组2.8%,伏诺拉生10mg组0.5%,伏诺拉生20mg组1.5%。
  • 延伸研究事后分析溃疡复发率比较:伏诺拉生10mg vs 兰索拉唑15mg,P=0.039;伏诺拉生20mg vs 兰索拉唑15mg,P=0.260。

临床怎么用

  • 原文结论认为伏诺拉生10mg和20mg在低剂量阿司匹林治疗期间预防溃疡复发与兰索拉唑15mg同样有效。
  • 原文结论认为伏诺拉生长期安全性相似且耐受良好。

局限性

  • 延伸研究中的溃疡复发率比较为事后分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Compare efficacy and safety of vonoprazan and lansoprazole for secondary prevention of low-dose aspirin (LDA)-associated peptic ulcers in a 24-week study and long-term extension therapy in separate study. DESIGN: Double-blind, randomised, non-inferiority study; single-blind extension study at 104 Japanese sites, including 621 patients (439 in extension) with a history of peptic ulcers who required long-term LDA therapy. Randomised (1:1:1, computer generated) patients received lansoprazole 15 mg (n=217), vonoprazan 10 mg (n=202) or vonoprazan 20 mg (n=202) once daily for 24 weeks (double blind) and ≤2 years (extension). The following measurements were made: 24-week (primary outcome; double blind) and 12-week peptic ulcer recurrence rate, 24-week GI bleeding rate, cumulative incidences of peptic ulcer recurrence and GI bleeding, treatment-emergent adverse events, laboratory results, serum gastrin and pepsinogen I/II concentrations. RESULTS: The 24-week peptic ulcer recurrence rate was 2.8%, 0.5% and 1.5% in the lansoprazole 15 mg, vonoprazan 10 mg and vonoprazan 20 mg groups, respectively. Vonoprazan was non-inferior (Farrington and Manning test: margin 8.7%, significance level 2.5%) to lansoprazole. In the post hoc analyses of the extension study, peptic ulcer recurrence rates were significantly lower with vonoprazan 10 mg (log-rank test, P=0.039), but not vonoprazan 20 mg (P=0.260), compared with lansoprazole 15 mg. GI bleeding rates were higher with lansoprazole compared with two doses of vonoprazan in both 24-week study and extension study. CONCLUSION: Vonoprazan (10 and 20 mg) was as effective as lansoprazole (15 mg) in preventing peptic ulcer recurrence during LDA therapy, had a similar long-term safety profile and was well tolerated. TRIAL REGISTRATION NUMBERS: NCT01452763; NCT01456247.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Kawai T, Oda K, Funao N, et al. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut. 2017. PMID: 29196436. doi:10.1136/gutjnl-2017-314852

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。